Purdue Pharma supports state Rx monitoring programs
CHARLESTON, S.C. Drug maker Purdue Pharma has donated $200,000 to the National Association of State Controlled Substances Authorities to address the abuse of prescription drugs, NASCSA said Tuesday.
The grant, presented at the group’s annual conference in Charleston, S.C., is designed to support state prescription drug monitoring programs. The NASCSA will be in charge of distributing the money to state agencies. Purdue is the maker of OxyContin (oxycodone), a commonly abused prescription opioid painkiller.
“State budgets are shrinking, but the abuse and diversion of prescription drug problem is a growing concern,” NASCSA executive director Kathy Keough said. “Purdue Pharma’s funding of state prescription drug monitoring programs will help keep these medications out of the wrong hands while ensuring legitimate patients have access to the medications they need.”
Teva, Sandoz launch Prevacid SoluTab generics
JERUSALEM The Food and Drug Administration granted approval for Teva’s abbreviated new drug application to market a generic version of a drug designed to treat peptic ulcers.
The generic drug maker said that its drug, lansoprazole, is a generic version of Takeda’s Prevacid SoluTab. Annual sales of the branded product were approximately $453 million in the United States, according to IMS sales data.
Sandoz, the generics division of Swiss drug maker Novartis, also announced the launch of its own version of Prevacid SoluTab.
FDA OKs expanded use of Baraclude
PRINCETON, N.J. The Food and Drug Administration has approved an additional use for a hepatitis drug.
Bristol-Myers Squibb announced Monday the approval of Baraclude (entecavir) as a treatment for chronic hepatitis B in adults with decompensated liver disease. The drug already is approved for adults with evidence of active viral replication.
“This additional indication for Baraclude is important news as it is now proven to be an effective treatment option for physicians to help in managing chronic hepatitis B patients with decompensated liver disease,” University of Hawaii professor of medicine Naoky Tsai said.